Version 1
: Received: 6 September 2024 / Approved: 9 September 2024 / Online: 9 September 2024 (11:18:39 CEST)
How to cite:
Eltit, I.; Juri, D.; Delgado, I.; Caceres, C.; Rojas, I.; Fernandez, M. I. Prevalence of Multimorbidity in Genitourinary Cancer in Chile: A Retrospective Population-Based Study. Preprints2024, 2024090661. https://doi.org/10.20944/preprints202409.0661.v1
Eltit, I.; Juri, D.; Delgado, I.; Caceres, C.; Rojas, I.; Fernandez, M. I. Prevalence of Multimorbidity in Genitourinary Cancer in Chile: A Retrospective Population-Based Study. Preprints 2024, 2024090661. https://doi.org/10.20944/preprints202409.0661.v1
Eltit, I.; Juri, D.; Delgado, I.; Caceres, C.; Rojas, I.; Fernandez, M. I. Prevalence of Multimorbidity in Genitourinary Cancer in Chile: A Retrospective Population-Based Study. Preprints2024, 2024090661. https://doi.org/10.20944/preprints202409.0661.v1
APA Style
Eltit, I., Juri, D., Delgado, I., Caceres, C., Rojas, I., & Fernandez, M. I. (2024). Prevalence of Multimorbidity in Genitourinary Cancer in Chile: A Retrospective Population-Based Study. Preprints. https://doi.org/10.20944/preprints202409.0661.v1
Chicago/Turabian Style
Eltit, I., Ignacio Rojas and Mario I. Fernandez. 2024 "Prevalence of Multimorbidity in Genitourinary Cancer in Chile: A Retrospective Population-Based Study" Preprints. https://doi.org/10.20944/preprints202409.0661.v1
Abstract
Abstract
Introduction and Objectives
Multimorbidity, defined as the coexistence of two or more chronic conditions, poses significant challenges in healthcare by affecting patient outcomes and increasing costs. This study aimed to evaluate multimorbidity's impact on patients with genitourinary cancer (GUC) in Chile, focusing on prevalent comorbidities, their combinations, and their association with hospitalization severity.
Materials and Methods
A retrospective, population-based study was conducted using data from the Fondo Nacional de Salud (FONASA) in Chile, including patients with bladder, prostate, kidney, and testicular cancer between 2019 and 2021. Diagnosis-related group (DRG) data were used to analyze comorbidity prevalence, hospitalization type (elective vs. emergency), severity (moderate/major vs. minor/none), length of stay, and associated costs.
Results
Among 4,028,597 hospital events, 11.6% were related to GUC, involving 18,792 patients. Multimorbidity was present in 67.3% of patients, with hypertension and diabetes being the most common comorbidities. These patients accounted for 69.1% of total GUC care costs. Hospital mortality was higher in multimorbid patients (7.5% vs. 3.7%; P
Keywords
Multimorbidity; Genitourinary Cancer; cancer costs; healthcare system burden
Subject
Medicine and Pharmacology, Urology and Nephrology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
